# US 2024/0189288 A1 · Treatment of glaucoma using endothelin receptor antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189288 A1
- Document ID: US20240189288A1
- Status: Published application
- Kind: A1
- Application number: 18/345,514
- Filed: 2023-06-30
- Published: 2024-06-13
- Earliest claimed: 2019-10-30
- Assignees: Perfuse Therapeutics, Inc.
- Applicants: Perfuse Therapeutics, Inc.
- Inventors: Sevgi Gurkan; David Floyd
- Web page: https://patentgrep.com/patent/US20240189288A1

## CPC

- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/0051: {Ocular inserts or implants}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to the discovery that certain diseases of the eye that profoundly affect the human visual system and, as a result, quality of life, may be treated using Edonentan or A-182086. Edonentan or A-182086 can be used alone or in combination with an intra-ocular pressure (IOP) reducing agent, a neuroprotective agent, an anti-VEGF agent, or all, for example. Using Edonentan or A-182086, alone or in combination with an additional agent, provides increased perfusion to the retina in certain diseases and reduces damage to retinal cells.

## Claims

### Claim at position 1

1-24. (canceled)

### Claim 25

A method of improving a visual function in a subject diagnosed with glaucoma, wherein the method comprises administering a therapeutically effective amount of edonentan, or a pharmaceutically acceptable salt thereof, in an optical tissue of said subject.

### Claim 26 (depends on 25)

The method of claim 25, wherein the visual function is selected from the group consisting of peripheral vision, central vision, contrast sensitivity, and nerve fiber layer thickness.

### Claim 27 (depends on 25)

The method of claim 25, wherein the administering comprises injecting edonentan to the back of the eye.

### Claim 28 (depends on 27)

The method of claim 27, wherein the injecting comprises injecting edonentan via a targeted drug delivery system, wherein the targeted drug delivery system is selected from the group consisting of Nanoporous Silicon, Port Delivery System (PDS), PEG-PLA Microspheres, MicroPump, Microneedle Injector, Needle-less Injectors, and Nanoliposomes.

### Claim 29 (depends on 27)

The method of claim 27, wherein the injecting comprises injecting edonentan to the back of the eye using an intravitreal, suprachoroidal, subretinal, or implant delivery platform.

### Claim 30 (depends on 27)

The method of claim 27, wherein the injecting comprises injecting edonentan to the back of the eye using an intravitreal, suprachoroidal, or implant delivery platform with a frequency of every 3 to 12 months.

### Claim 31 (depends on 27)

The method of claim 27, wherein the injecting comprises injecting edonentan to the back of the eye using an intravitreal, suprachoroidal, or implant delivery platform with a frequency of every 3 to 6 months.

### Claim 32 (depends on 27)

The method of claim 27, wherein the injecting comprises injecting edonentan to the back of the eye using an intravitreal, suprachoroidal, or implant delivery platform with a frequency of every 4 to 6 months.

### Claim 33

A method of improving a visual function in a subject diagnosed with glaucoma, wherein the method comprises administering about 50 μg to about 4 mg of edonentan, or a pharmaceutically acceptable salt thereof, in an optical tissue of said subject.

### Claim 34 (depends on 33)

The method of claim 33, wherein the visual function is selected from the group consisting of peripheral vision, central vision, contrast sensitivity, and nerve fiber layer thickness.

### Claim 35 (depends on 33)

The method of claim 33, wherein the administering comprises injecting edonentan to the back of the eye.

### Claim 36 (depends on 35)

The method of claim 35, wherein the injecting comprises injecting edonentan via a targeted drug delivery system, wherein the targeted drug delivery system is selected from the group consisting of Nanoporous Silicon, Port Delivery System (PDS), PEG-PLA Microspheres, MicroPump, Microneedle Injector, Needle-less Injectors, and Nanoliposomes.

### Claim 37 (depends on 35)

The method of claim 35, wherein the injecting comprises injecting edonentan to the back of the eye using an intravitreal, suprachoroidal, subretinal, or implant delivery platform.

### Claim 38 (depends on 35)

The method of claim 35, wherein the injecting comprises injecting edonentan to the back of the eye using an intravitreal, suprachoroidal, or implant delivery platform with a frequency of every 3 to 12 months.

### Claim 39 (depends on 35)

The method of claim 35, wherein the injecting comprises injecting edonentan to the back of the eye using an intravitreal, suprachoroidal, or implant delivery platform with a frequency of every 3 to 6 months.

### Claim 40 (depends on 35)

The method of claim 35, wherein the injecting comprises injecting edonentan to the back of the eye using an intravitreal, suprachoroidal, or implant delivery platform with a frequency of every 4 to 6 months.

### Claim 41

A method of improving optic nerve head blood flow in a subject diagnosed with glaucoma, wherein the method comprises administering a therapeutically effective amount of edonentan, or a pharmaceutically acceptable salt thereof, in an optical tissue of said subject.

### Claim 42 (depends on 41)

The method of claim 41, wherein the administering comprises injecting edonentan to the back of the eye.

### Claim 43 (depends on 42)

The method of claim 42, wherein the injecting comprises injecting edonentan via a targeted drug delivery system, wherein the targeted drug delivery system is selected from the group consisting of Nanoporous Silicon, Port Delivery System (PDS), PEG-PLA Microspheres, MicroPump, Microneedle Injector, Needle-less Injectors, and Nanoliposomes.

### Claim 44 (depends on 42)

The method of claim 42, wherein the injecting comprises injecting edonentan to the back of the eye using an intravitreal, suprachoroidal, subretinal, or implant delivery platform.

### Claim 45 (depends on 42)

The method of claim 42, wherein the injecting comprises injecting edonentan to the back of the eye using an intravitreal, suprachoroidal, or implant delivery platform with a frequency of every 3 to 12 months.

### Claim 46 (depends on 42)

The method of claim 42, wherein the injecting comprises injecting edonentan to the back of the eye using an intravitreal, suprachoroidal, or implant delivery platform with a frequency of every 3 to 6 months.

### Claim 47 (depends on 42)

The method of claim 42, wherein the injecting comprises injecting edonentan to the back of the eye using an intravitreal, suprachoroidal, or implant delivery platform with a frequency of every 4 to 6 months.
